170 related articles for article (PubMed ID: 37791673)
1. Effects of concomitant use of THC and irinotecan on tumour growth and biochemical markers in a syngeneic mouse model of colon cancer.
Žunec S; Karačonji IB; Čatalinac M; Jurič A; Katić A; Kozina G; Micek V; Neuberg M; Vrdoljak AL
Arh Hig Rada Toksikol; 2023 Sep; 74(3):198-206. PubMed ID: 37791673
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.
Lucić Vrdoljak A; Fuchs N; Mikolić A; Žunec S; Brčić Karačonji I; Jurič A; Prester L; Micek V; Neuberg M; Čanović S; Mršić G; Kopjar N
Molecules; 2018 Jun; 23(6):. PubMed ID: 29865166
[TBL] [Abstract][Full Text] [Related]
3. Effects of Δ
Prester L; Mikolić A; Jurič A; Fuchs N; Neuberg M; Lucić Vrdoljak A; Brčić Karačonji I
Chem Biol Interact; 2018 Oct; 294():128-134. PubMed ID: 30130528
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Nov; 446():1-317. PubMed ID: 12594529
[TBL] [Abstract][Full Text] [Related]
5. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ
Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
[TBL] [Abstract][Full Text] [Related]
6. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
Huisman SA; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; IJzermans JN; Wiemer EA; Mathijssen RH; de Bruin RW
Br J Pharmacol; 2016 Mar; 173(5):804-14. PubMed ID: 26332723
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of a gas chromatography-mass spectrometry method for the simultaneous determination of tetrahydrocannabinol and its metabolites in rat urine.
Fuchs N; Miljanić A; Katić A; Brajenović N; Micek V; Fuchs R; Karačonji IB
Arh Hig Rada Toksikol; 2019 Dec; 70(4):325-331. PubMed ID: 32623866
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.
Coskun ZM; Bolkent S
Cell Biochem Funct; 2014 Oct; 32(7):612-9. PubMed ID: 25187240
[TBL] [Abstract][Full Text] [Related]
9. Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice.
Pinto CE; Moura E; Serrão MP; Martins MJ; Vieira-Coelho MA
Braz J Med Biol Res; 2010 Apr; 43(4):325-9. PubMed ID: 20445947
[TBL] [Abstract][Full Text] [Related]
10. High Doses of Δ
Kopjar N; Fuchs N; Brčić Karačonji I; Žunec S; Katić A; Kozina G; Lucić Vrdoljak A
Clin Drug Investig; 2020 Sep; 40(9):775-787. PubMed ID: 32696321
[TBL] [Abstract][Full Text] [Related]
11. Development and Evaluation of Biotin Functionalized Fullerenes for the Delivery of Irinotecan to Colon Tumors.
Dhiman S; Kaur A; Gupta GL; Sharma M
Curr Drug Deliv; 2023; 20(7):978-991. PubMed ID: 35578876
[TBL] [Abstract][Full Text] [Related]
12. Curcumin Suppresses the Progression of Colorectal Cancer by Improving Immunogenic Cell Death Caused by Irinotecan.
Zhu C; Fang Z; Peng L; Gao F; Peng W; Song F
Chemotherapy; 2022; 67(4):211-222. PubMed ID: 36380644
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration with tetrahydrocannabinol causes retinal damage in BALB/c mice.
Zhang Z; Li R; Lu H; Zhang X
Hum Exp Toxicol; 2020 Mar; 39(3):290-300. PubMed ID: 31680560
[TBL] [Abstract][Full Text] [Related]
14. Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: Preparation, in-vitro and in-vivo evaluations.
Bhaskaran NA; Jitta SR; Salwa ; Cheruku S; Kumar N; Kumar L
Int J Biol Macromol; 2022 Jun; 211():301-315. PubMed ID: 35568152
[TBL] [Abstract][Full Text] [Related]
15. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Guzmán M; Duarte MJ; Blázquez C; Ravina J; Rosa MC; Galve-Roperh I; Sánchez C; Velasco G; González-Feria L
Br J Cancer; 2006 Jul; 95(2):197-203. PubMed ID: 16804518
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Kauffels A; Nowack H; Bohnenberger H; Spitzner M; Sprenger T; Ghadimi M; Sperling J
Clin Exp Metastasis; 2023 Jun; 40(3):235-242. PubMed ID: 37093320
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model.
Huang JR; Lee MH; Li WS; Wu HC
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30818855
[TBL] [Abstract][Full Text] [Related]
19. Tolerance to the effect of delta1-tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol.
Pertwee RG
Br J Pharmacol; 1974 Jul; 51(3):391-7. PubMed ID: 4451752
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.
Hernán Pérez de la Ossa D; Lorente M; Gil-Alegre ME; Torres S; García-Taboada E; Aberturas Mdel R; Molpeceres J; Velasco G; Torres-Suárez AI
PLoS One; 2013; 8(1):e54795. PubMed ID: 23349970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
